RxDoctor Payments Data

Vu Hoang, MD

Cardiovascular Disease · Houston, TXNPI 1689968885

Payments from drug & device makers

$3,203in general payments, 2019–2025

Across 112 payments — averaging $28.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$653
  • Johnson & Johnson$315
  • Novartis$264
  • E.r. Squibb & Sons, L.L.C.$218
  • Sanofi-aventis U.S. LLC$133
  • plus $457 from 8 others

What the payments were for

  • Food & beverage$3,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,203 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$487,802
Medicare patients
429
Services billed
5,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$174,546
XareltoRivaroxaban39$42,329
EntrestoSacubitril/Valsartan14$17,744
VascepaIcosapent Ethyl28$17,085
Ranolazine ErRanolazine68$5,302
Amiodarone Hcl43$2,888
Metoprolol Succinate239$2,067
Atorvastatin Calcium322$2,011
Digoxin20$1,915
Losartan Potassium243$1,501
Nifedipine ErNifedipine42$1,298
Amlodipine Besylate250$1,153
Carvedilol114$936
Isosorbide Dinitrate21$762
ClopidogrelClopidogrel Bisulfate136$758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$174,546141 claims
Johnson & JohnsonXarelto$315$42,32939 claims
NovartisEntresto$264$17,74414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →